CXCL13 and kidney cancer: Higher expression of LAG3, PDCD1, and TIGIT showed the worst survival outcome of anti-ICB therapy in kidney cancer indication drug resistance [24], whereas high LAG3 and CXCL13 expressions were associated with better survival of anti-PDL1 therapy in metastatic BLCA [25], indicating drug sensitivity.